A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This is a study to investigate if eltrombopag can be used instead of Intravenous Immune
Globulin (IVIG) in patients with ITP, to adequately raise their platelet count when they
undergo minor or major surgery. Eltrombopag is a daily, oral pill approved for treatment of
ITP. IVIG is a blood product frequently used to treat ITP. Patients with ITP who need surgery
have to get treatment to increase their platelet count. IVIG is commonly used for this
purpose but eltrombopag may be more effective and convenient for patients.
Phase:
Phase 3
Details
Lead Sponsor:
McMaster University
Collaborators:
GlaxoSmithKline Hamilton Health Sciences Corporation Novartis